{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pruritus-ani/prescribing-information/topical-treatments/","result":{"pageContext":{"chapter":{"id":"09b13ce9-39e9-5967-be36-6d6ad4971b30","slug":"topical-treatments","fullItemName":"Topical treatments","depth":2,"htmlHeader":"<!-- begin field e769f6c6-4e78-4d65-bbf9-304cff1608d8 --><h2>Which topical preparation should I prescribe or recommend?</h2><!-- end field e769f6c6-4e78-4d65-bbf9-304cff1608d8 -->","summary":"","htmlStringContent":"<!-- begin item 0c077e0b-62a3-4b6a-93b0-65023cafcb1d --><!-- begin field 89aba76d-78d7-4569-bf02-8be1c74659a6 --><ul><li><strong>If the perianal skin is excoriated, </strong>consider prescribing a soothing cream or ointment, such as one containing bismuth subgallate or zinc oxide.<ul><li>Some haemorrhoidal preparations, such as Anusol<sup>®</sup> and Germoloids<sup>®</sup> cream and ointment, are also licensed for the symptomatic relief of pruritus ani. </li><li>Advise the person that: <ul><li>Generally, the cream or ointment should be applied to clean, dry skin at night, in the morning, and after each bowel movement. Detailed information on how to use each individual product can be found in the product's Patient Information Leaflet (PIL).</li><li>They should seek medical advice if symptoms worsen or persist beyond 3–6 weeks. </li></ul></li></ul></li><li><strong>If t</strong><strong>he perianal skin is inflamed, </strong>consider prescribing a mildly potent topical corticosteroid (such as hydrocortisone 1% cream or ointment).<ul><li>Some corticosteroid-containing haemorrhoidal preparations, such as Anusol-HC<sup>®</sup> ointment (which contains hydrocortisone 0.25%) and Proctosedyl<sup>®</sup> ointment (which contains hydrocortisone 0.5%), are also licensed for the short term relief of pruritus ani. </li><li>Do not prescribe a topical corticosteroid if the person has localized infections, such as herpes simplex infection or perianal thrush.</li><li>Advise the person that: <ul><li>Generally, the cream or ointment should be applied to clean, dry skin at night, in the morning, and after each bowel movement. Detailed information on how to use each individual product can be found in the product's Patient Information Leaflet (PIL).</li><li>Topical corticosteroids should be applied thinly (to reduce the risk of systemic absorption through the rectal mucosa), up to a maximum of 2 applications a day, and for no longer than 7 days (as prolonged use may lead to skin atrophy, contact dermatitis, and skin sensitization). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a> for detailed information on prescribing topical corticosteroids.</li></ul></li></ul></li><li><strong>No topical preparations are licensed for use during pregnancy or breastfeeding. </strong>However, the potential risk of harms to the pregnant woman and/or the fetus or infant is likely to be less with simple, soothing products than with those containing corticosteroid (which are generally not recommended by the manufacturers for use during pregnancy due to inadequate safety evidence).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pruritus-ani/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pruritus-ani/references/\">ABPI, 2016c</a>]</p><!-- end field 89aba76d-78d7-4569-bf02-8be1c74659a6 --><!-- end item 0c077e0b-62a3-4b6a-93b0-65023cafcb1d -->","topic":{"id":"87896ca6-9aaa-5f82-80d8-9af6e6a4a7a9","topicId":"86164793-614e-4454-88db-d9e55aaa253a","topicName":"Pruritus ani","slug":"pruritus-ani","lastRevised":"Last revised in July 2016","chapters":[{"id":"f9039630-6980-5e4d-8b53-5f4a9a150404","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b6f70111-057f-5e18-8eca-73d22e7a37fc","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"8b745278-e643-5f46-874e-0e59cc2271b0","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2c6c2bd2-2780-5cda-90cd-0f0f1b291a90","slug":"changes","fullItemName":"Changes"},{"id":"57503895-5e7b-5b94-92cd-1d1516ca3df8","slug":"update","fullItemName":"Update"}]},{"id":"a3d4f578-5b09-55d8-b87e-5f3b001dacc0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ac52f024-a697-5997-b42a-163c6af60168","slug":"goals","fullItemName":"Goals"},{"id":"5f9315d6-bd64-5333-8d5c-94650869661f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3819cff6-e1c5-5c6b-bd42-a3230e0dee66","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e5f4211b-d307-5395-8284-4852182fe149","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7288ccfe-7870-538b-b8ea-c991d02b41a4","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4d207031-7d03-5c1c-862d-e2bc91d5f92b","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"bd580148-0cf8-5dfd-ad32-519d9ac91ac6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d3973039-47c7-5366-9ce0-805dad2adffa","slug":"definition","fullItemName":"Definition"},{"id":"d40db160-dd24-516c-830c-f5d2ea3e292f","slug":"causes","fullItemName":"Causes"},{"id":"563df3bd-d0d2-5da3-b9d8-b9926d46f9d3","slug":"prognosis","fullItemName":"Prognosis"},{"id":"3190f567-6879-5e17-afa2-938933b25cdf","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4dc56a97-ed78-5d3d-a7db-9fb8e99b315e","slug":"complications","fullItemName":"Complications"}]},{"id":"9240f15c-a3da-584f-a0c8-c129c79e4e32","fullItemName":"Management","slug":"management","subChapters":[{"id":"8b65829f-1484-5434-8d10-e778dcf736be","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"168bc91f-4693-57bd-a8d8-f94f8de33fe3","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"09b13ce9-39e9-5967-be36-6d6ad4971b30","slug":"topical-treatments","fullItemName":"Topical treatments"},{"id":"37717bd2-4921-5290-a6b8-f0a65ad0f747","slug":"chlorphenamine","fullItemName":"Chlorphenamine"}]},{"id":"81333760-2198-5943-b67a-82171b83e114","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"54290b12-c53b-5540-82ca-813deeebd19b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1fa3fbc1-b2c7-52ef-9dea-ae8969093694","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c5b0b77c-5a39-5707-8719-949dd0d0c26e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"eac83458-255c-54b9-a370-647761527867","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3b5e6536-aea6-5811-b6cc-15c63a12d8fe","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1850e7a5-28b3-5f26-adc1-18d76f0d8848","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"85d0bc6e-70f1-5259-b3e0-164f534bd071","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"168bc91f-4693-57bd-a8d8-f94f8de33fe3","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}